USFDA concludes inspection at Zydus Lifesciences Ahmedabad site with zero observations
Zydus Lifesciences Ahmedabad Topical Manufacturing site gets zero USFDA observations
Ahmedabad: Zydus Lifesciences has informed in a BSE filing that the US Food and Drug Administration (USFDA) has concluded a routine surveillance inspection with NIL observations at the group’s Topical Manufacturing site situated at Changodar in Ahmedabad.
The inspection was conducted from February 10th to 14th, 2025.
Medical Dialogues team had earlier reported that the Company had successfully completed a USFDA surveillance inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Ambernath, Maharashtra.
Read also: Zydus' Ambernath API Plant Clears USFDA Inspection with Zero Observations
Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs.
Read also: Zydus inks pact with Beihai Biotech for cancer drug Beizray commercialization in US
